Trimetazidine and allopurinol for the prevention of Contrast-associated acute kidney injury in elective percutaneous coronary intervention: a randomized controlled trial
The TMZ-allopurinol combination showed a favorable but non-significant trend toward reducing CA-AKI, while ACEF and Mehran scores demonstrated limited predictive value. Improved risk-stratification tools and larger studies in higher-risk patients are needed. SGLT2 and DPP-4 inhibitors showed smaller creatinine increases, suggesting possible nephroprotection, but this remains exploratory.
Authors
- Naglaa Samir Bazan (ORCID: https://orcid.org/0000-0002-8930-4697)
- Mohamed E. A. Abdelrahim (ORCID: https://orcid.org/0000-0003-0227-8404)
- Hatem Hossam Mowafy
- Nissa J. Ali (ORCID: https://orcid.org/0000-0002-8644-9583)
- Hadeer Safwat Harb
Institutions
- Beni-Suef University (EG)
- Cairo University (EG)
- Egyptian Government (EG)
- King Khalid University (SA)
Publication Details
- Journal
- European Journal of Clinical Pharmacology
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1007/s00228-025-03985-6
- Primary Topic
- Acute Kidney Injury Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cairo University